CST, 14975T, beta-Amyloid (pE3 Peptide) (D5N5H) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying Beta-APP(pE3-42). Validated for Western Blotting,Immunohistochemistry (Paraffin),Immunofluorescence (Frozen). Available in 2 sizes. Highly specific and rigorously validated in-house, beta-Amyloid (pE3 Peptide) (D5N5H) Rabbit Monoclonal Antibody (CST #14975) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunohistochemistry (Paraffin): 1:100 Immunofluorescence (Frozen): 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 76486 . Protocol Available protocols: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence (Frozen) Specificity / Sensitivity beta-Amyloid (pE3 Peptide) (D5N5H) Rabbit Monoclonal Antibody recognizes recombinant pE3 form of β-amyloid peptides. This antibody does not cross-react with the non-pyroglutamate (E3) form of β-amyloid peptides. Species Reactivity: Human Source / Purification Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of β-amyloid (pE3) peptide. Background Amyloid β (Aβ) precursor protein (APP) is a 100-140 kDa transmembrane glycoprotein that exists as several isoforms (1). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (1). The extracellular deposition and accumulation of the released Aβ fragments form the main components of amyloid plaques in Alzheimer's disease (1). APP can be phosphorylated at several sites, which may affect the proteolytic processing and secretion of this protein (2-5). Phosphorylation at Thr668 (a position corresponding to the APP695 isoform) by cyclin-dependent kinase is cell-cycle dependent and peaks during G2/M phase (4). APP phosphorylated at Thr668 exists in adult rat brain and correlates with cultured neuronal differentiation (5,6). Aβ peptides can be further modified by amino-terminal truncation that exposes a free glutamate residue to the enzyme glutaminyl cyclase, which catalyzes the formation of an amino-terminal pyroglutamate (pE) (7,8). Aβ (pE3) peptides exhibit increased stability relative to non-modified peptides due to an enhanced resistance to peptidase-mediated degradation (9) and a higher propensity to form β-sheets and aggregate (10). Antibodies targeting Aβ (pE3) peptides may be plaque-specific as there is no evidence for circulating Aβ (pE3) peptides (11). Alternate Names A4; AAA; ABETA; Abeta40; Abeta42; ABPP; AD1; AICD-50; AICD-57; AICD-59; AID(50); AID(57); AID(59); Alpha-CTF; Alpha-secretase C-terminal fragment; Alzheimer disease amyloid protein; Amyloid beta; amyloid beta (A4) precursor protein; Amyloid beta A4 protein; amyloid beta precursor protein; Amyloid intracellular domain 50; Amyloid intracellular domain 57; Amyloid intracellular domain 59; Amyloid precursor protein; Amyloid-beta A4 protein; Amyloid-beta precursor protein; Amyloid-beta protein 40; Amyloid-beta protein 42; APP; APPI; Beta Amyloid; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); beta-amyloid precursor protein; Beta-amyloid protein 40; Beta-amyloid protein 42; Beta-APP40; Beta-APP42; Beta-CTF; Beta-secretase C-terminal fragment; C31; C80; C83; C99; Cerebral vascular amyloid peptide; CTFgamma; CVAP; Gamma-CTF(50); Gamma-CTF(57); Gamma-CTF(59); Gamma-secretase C-terminal fragment 50; Gamma-secretase C-terminal fragment 57; Gamma-secretase C-terminal fragment 59; N-APP; P3(40); P3(42); peptidase nexin-II; PN-II; PN2; PreA4; Protease nexin-II; S-APP-alpha; S-APP-beta; Soluble APP-alpha; Soluble APP-beta; testicular tissue protein Li 2 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 4 Source/Isotype: Rabbit IgG